AZN vs NVO
AstraZeneca PLC and Novo Nordisk A/S, both Healthcare
AstraZeneca PLC is the larger company at $288B against $211B. Over the past year AZN returned +5.4% against -35% for NVO. The RyuScore puts NVO ahead, 88 against 60 out of 100.
| Figure | AZN | NVO |
|---|---|---|
| Last close | $159 | $38.62 |
| Market cap | $288B | $211B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 26.2 | n/a |
| 1-year return | +5.4% | -35% |
| 5-year return | +57% | -15% |
| RyuScoresector-relative, 1–10 | 60/100 | 88/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AstraZeneca PLC
Revenue of $31B in H2 2025, net income $4.9B.
Novo Nordisk A/S
Open these two in the interactive comparison to add more names, change the period or see the correlation.